Stockreport

INmune Bio's unique Alzheimer's trial endpoint receives validation [Yahoo! Finance]

INmune Bio Inc. - Common stock  (INMB) 
PDF The AD02 trial (NCT05318976), investigating INmune's tumour necrosis factor (TNF) XPro, is using Early Mild Alzheimer's Cognitive Composite (EMACC) as a primary endpoin [Read more]